Answers are grounded in this paper and cite their sources.
Background and purpose Refractory invasive pulmonary fungal infection (RIPFI) carries high mortality in hematological patients after first-line treatment failure. We evaluated the clinical response and safety of salvage therapy with bronchoscopic amphotericin B instillation (BABI) plus systemic antifungals in a retrospective cohort. Methods We retrospectively analyzed hematological patients with RIPFI receiving salvage therapy from 2019 to 2024. Clinical response was defined as complete/partial response (EORTC/MSG criteria). Univariable regression analysis was performed to explore factors potentially associated with treatment response. Results During a limited median follow-up of 67 days (IQR 49–76) covering all 97 patients, no deaths or serious adverse events occurred. After this period, 43 patients were transferred back to referring hospitals and were lost to further follow-up, while 54 patients continued follow-up at our center. Adverse events were infrequent (drug‑related: 16.5%; procedure‑related: 14.4%), mild, and resolved without treatment interruption. Patients received a median of 1 BABI procedure (IQR 1–3) in addition to systemic antifungal therapy. A clinical response was observed in 56.7% of patients (55 of 97). Univariable analysis suggested that several factors were associated with treatment response. Conclusions In this retrospective cohort, BABI plus systemic antifungals demonstrated acceptable safety and tolerability in selected hematological patients with RIPFI during limited follow‑up. Exploratory clinical response data are also presented, but causality cannot be established due to the lack of a control group. These exploratory findings require confirmation in prospective, controlled studies.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: